76318-50-8

Usage

Uses

Used in Pharmaceutical Synthesis:
METHYL 3,5-DIIODO-L-TYROSINATE is used as an intermediate in the synthesis of pharmaceuticals for its ability to modulate biological processes and contribute to the development of new drugs and treatments.
Used in Research Chemicals:
In the field of research chemicals, METHYL 3,5-DIIODO-L-TYROSINATE is utilized as a building block for the creation of more complex molecules, facilitating advancements in scientific research and drug discovery.
Used in Medical Research:
METHYL 3,5-DIIODO-L-TYROSINATE is employed in medical research for its potential to modulate biological processes, making it a valuable component in the exploration of new treatments and therapies.
Used in Drug Discovery:
METHYL 3,5-DIIODO-L-TYROSINATE is used in drug discovery as a valuable component due to its unique structure and functional groups, which can contribute to the development of innovative drugs and treatments.

InChI:InChI=1/C10H11I2NO3/c1-16-10(15)8(13)4-5-2-6(11)9(14)7(12)3-5/h2-3,8,14H,4,13H2,1H3/t8-/m1/s1

Upstream product

• 1080-06-4 L-Tyr-OMe 
• 60-18-4 L-tyrosine 
• 67-56-1 methanol 
• 300-39-0 3,5-diiodo-l-tyrosine 

Downstream Products

• 95253-83-1 3.5-diiodo-N-(N-benzyloxycarbonyl-α-L-glutamyl)-L-tyrosine 
• 128781-80-6 (S)-methyl 2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-3,5-diiodophenyl)propanoate 
• 123418-40-6 (9S,12S,15S)-9-Acetylamino-12-(4-benzyloxy-benzyl)-5-chloro-4-hydroxy-19,20-diiodo-10,13-dioxo-2-oxa-11,14-diaza-tricyclo[15.2.2.1^3,7]docosa-1⁽²⁰⁾,3,5,7⁽²²⁾,17⁽²¹⁾,18-hexaene-15-carboxylic acid methyl ester 
• 123418-39-3 (9S,12S,15S)-15-Acetylamino-12-(4-benzyloxy-benzyl)-19,20-dichloro-4-hydroxy-5-iodo-11,14-dioxo-2-oxa-10,13-diaza-tricyclo[15.2.2.1^3,7]docosa-1⁽²⁰⁾,3⁽²²⁾,4,6,17⁽²¹⁾,18-hexaene-9-carboxylic acid methyl ester 
• 123418-38-2 N-acetyl-3,5-dichloro-L-tyrosyl-O-benzyl-L-tyrosyl-3,5-diiodo-L-tyrosinemethyl ester 
• 123418-37-1 (S)-2-[(S)-2-Amino-3-(4-benzyloxy-phenyl)-propionylamino]-3-(4-hydroxy-3,5-diiodo-phenyl)-propionic acid methyl ester; hydrochloride 
• 123418-35-9 (9S,12S,15S)-9-Acetylamino-4-hydroxy-12-(4-hydroxy-benzyl)-10,13-dioxo-2-oxa-11,14-diaza-tricyclo[15.2.2.1^3,7]docosa-1⁽²⁰⁾,3,5,7⁽²²⁾,17⁽²¹⁾,18-hexaene-15-carboxylic acid methyl ester 
• 123418-36-0 (9S,12S,15S)-9-Acetylamino-4-hydroxy-12-(4-hydroxy-benzyl)-10,13-dioxo-2-oxa-11,14-diaza-tricyclo[15.2.2.1^3,7]docosa-1⁽²⁰⁾,3,5,7⁽²²⁾,17⁽²¹⁾,18-hexaene-15-carboxylic acid 
• 120363-27-1 Methyl (9S,12S,15S)-15-(acetylamino)-4-hydroxy-12-<(4-hydroxyphenyl)methyl>-11,14-dioxo-2-oxa-10,13-diazatricyclo<15.2.2.1^3,7>docosa-3,5,7(22),17,19,20-hexaene-9-carboxylate 
• 108890-90-0 K-13 
• 56460-41-4 3.5-diiodo-N-acetyl-L-tyrosine methyl ester 

Relevant academic research and scientific papers

COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF

Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a SO2 functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.

A novel class of tyrosine derivatives as dual 5-LOX and COX-2/mPGES1 inhibitors with PGE2 mediated anticancer properties

Leukotriene and prostaglandin pathways are controlled by the enzymes, LOX and COX/mPGES1 respectively and are responsible for inflammatory responses. PGE2, produced by mPGES1, leads to the progression of inflammation as well as cancer. A series of 19 novel tyrosine derivatives are synthesized, characterized and tested against 5-LOX, in vitro, and production of PGE2, in HeLa cells. 6b-v and 6c-i, are found to possess maximum inhibitory action against 5-LOX and PGE2 production. The compound 6b-v is found to act by disrupting the redox cycle of the 5-LOX enzyme, and its activity is comparable to that of the commercial drug, Zileuton. The activity of the other compound 6c-i is comparable to a drug in clinical trials, Licofelone, and it has been found to inhibit the mRNA expression of mPGES1 predominantly. It also arrests the HeLa cells in the S and G2/M phases of the cell cycle indicating anticancer activity. Also, compounds, 6b-iv and 6b-viii inhibit both the LT & PG pathways in the inflammation cascade. Presence of iodine in the phenyl ring appears to favour the inhibition of 5-LOX whereas chlorine favours the inhibition of PGE2 production. These leads could be further optimized and developed as drugs against inflammation and cancer.

Tyrosine-derived stimuli responsive, fluorescent amino acids

A series of fluorescent unnatural amino acids (UAAs) bearing stilbene and meta-phenylenevinylene (m-PPV) backbone have been synthesized and their optical properties were studied. These novel UAAs were derived from protected diiodo-l-tyrosine using palladi

Iodination of aromatic residues in peptides by reaction with IPy2BF4

A simple and straightforward approach to selectively iodinate Tyr residues on peptides using IPy2BF4 is described which is compatible with Met residues on the side chain; preliminary studies reveal that the method is also suitable to